- WuXi Biologics is the only pharmaceutical company in the 2025 Hang Seng Corporate Sustainability Benchmark Index.
- The company supports 864 integrated client projects, including 24 in commercial manufacturing as of June 30, 2025.
- WuXi Biologics' greenhouse gas emissions-reduction targets were approved by the Science Based Targets initiative in August.
- The company has over 12,000 employees across China, the US, Ireland, Germany, and Singapore.
Inclusion in Sustainability Index
WuXi Biologics has been included in the 2025 Hang Seng Corporate Sustainability Benchmark Index, marking it as the only pharmaceutical company to receive this recognition. The index highlights companies with outstanding ESG performance, assessed annually by the Hong Kong Quality Assurance Agency.
Commitment to Sustainability
As a global provider of biologics Green CRDMO solutions, WuXi Biologics integrates sustainability into its business operations. The company focuses on optimizing energy and resource efficiency, enhancing governance transparency, and improving employee welfare and societal contributions.
Global Initiatives and Targets
Aligned with the United Nations Sustainable Development Goals, WuXi Biologics is engaged with the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative. Its greenhouse gas emissions-reduction targets were approved by the Science Based Targets initiative in August.
Recognition and Ratings
WuXi Biologics has received numerous accolades for its sustainability efforts, including an MSCI AAA ESG Rating, EcoVadis Platinum Medal, and inclusion in the Dow Jones Sustainability Indices. It has also been recognized by CDP for water security and climate change efforts, and rated highly by Sustainalytics and ISS ESG Corporate Rating.
Operational Scale
With over 12,000 employees across China, the United States, Ireland, Germany, and Singapore, WuXi Biologics supports 864 integrated client projects, including 24 in commercial manufacturing as of June 30, 2025.
